Table 1. Baseline characteristics of the patients with juvenile-onset SLE (jSLE) ‡.
| Characteristics | Obese (N=51) |
Non-obese (N=151) |
P-value* |
|---|---|---|---|
| Females | 40 | 124 | NS |
| Race | |||
| Asian | 0 | 19 | <0.0001** |
| African-American | 24 | 42 | |
| Caucasian | 27 | 90 | |
| Ethnicity | |||
| Hispanic | 6 | 23 | NS*** |
| Non-Hispanic | 45 | 128 | |
| Age (in years) | 15.4 ± 2.3 | 15.8 ± 3.1 | NS |
| Body Mass Index (BMI)Ŧ | |||
| Obese (BMI ≥ 95th percentile) | 51 | ||
| Overweight (BMI ≥ 85th but < 95th percentile) | 42 | ||
| Normal (BMI ≥ 5th but < 85th percentile) | 106 | ||
| Underweight (BMI < 5th percentile) | 3 | ||
| Daily prednisone dose (< 0.2 mg/kg) | 10 | 13 | 0.04 |
| Currently receiving methylprednisolone pulses | 6 | 28 | NS |
| Any immunosuppressive useŦŦ | 22 | 56 | NS |
| Low disease activity (SELENA-SLEDAI∫ < 4) | 19 | 45 | NS |
| Minimal disease damage (SDI∫∫ < 1) | 34 | 114 | NS |
Legend:
Values are N except for age which is shown as means ± standard deviation (SD); NS = not significant
P-value from A (obese jSLE) vs. B (non-obese jSLE)
BMI is weight in kilograms divided by height in meters squared (kg/m2). Classification is based on CDC 2000 gender-specific BMI-for-age reference (1)
P-value based on Fisher's exact test considering race (Asian, African-American and Caucasian) vs. obese/non-obese
P-value based on Fisher's exact test considering ethnicity (Hispanic and Non-Hispanic) vs. obese/non-obese
Any immunosuppressive use (i.e. mycophenolate mofetil, azathioprine, cyclophosphamide, and/or rituximab) during study period
Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index
SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index